CN105301127A - 一种利巴韦林药物组合物及其有关物质检测方法 - Google Patents
一种利巴韦林药物组合物及其有关物质检测方法 Download PDFInfo
- Publication number
- CN105301127A CN105301127A CN201510656048.2A CN201510656048A CN105301127A CN 105301127 A CN105301127 A CN 105301127A CN 201510656048 A CN201510656048 A CN 201510656048A CN 105301127 A CN105301127 A CN 105301127A
- Authority
- CN
- China
- Prior art keywords
- ribavirin
- injection
- pharmaceutical composition
- related substance
- medicinal composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title claims abstract description 85
- 229960000329 ribavirin Drugs 0.000 title claims abstract description 85
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 title claims abstract description 85
- 239000000126 substance Substances 0.000 title claims abstract description 30
- 238000001514 detection method Methods 0.000 title claims abstract description 8
- 239000000203 mixture Substances 0.000 title abstract description 7
- 238000002347 injection Methods 0.000 claims abstract description 43
- 239000007924 injection Substances 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000000243 solution Substances 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000008215 water for injection Substances 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 239000000047 product Substances 0.000 claims abstract description 5
- 230000001954 sterilising effect Effects 0.000 claims abstract description 5
- 238000001914 filtration Methods 0.000 claims abstract description 3
- 239000013067 intermediate product Substances 0.000 claims abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 18
- 239000012071 phase Substances 0.000 claims description 16
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 9
- 239000012488 sample solution Substances 0.000 claims description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000008346 aqueous phase Substances 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 239000012074 organic phase Substances 0.000 claims description 4
- 238000004811 liquid chromatography Methods 0.000 claims description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 3
- 235000011152 sodium sulphate Nutrition 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 9
- 238000012360 testing method Methods 0.000 abstract description 8
- 238000003908 quality control method Methods 0.000 abstract description 4
- 238000007865 diluting Methods 0.000 abstract 2
- 238000004128 high performance liquid chromatography Methods 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 238000005086 pumping Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000012535 impurity Substances 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 239000007791 liquid phase Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- HLGRRZFWTBVGMM-UHFFFAOYSA-L disodium;sulfate;dihydrate Chemical compound O.O.[Na+].[Na+].[O-]S([O-])(=O)=O HLGRRZFWTBVGMM-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510656048.2A CN105301127B (zh) | 2015-10-13 | 2015-10-13 | 一种利巴韦林药物组合物及其有关物质检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510656048.2A CN105301127B (zh) | 2015-10-13 | 2015-10-13 | 一种利巴韦林药物组合物及其有关物质检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105301127A true CN105301127A (zh) | 2016-02-03 |
CN105301127B CN105301127B (zh) | 2018-09-18 |
Family
ID=55198635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510656048.2A Active CN105301127B (zh) | 2015-10-13 | 2015-10-13 | 一种利巴韦林药物组合物及其有关物质检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105301127B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108434095A (zh) * | 2018-06-19 | 2018-08-24 | 吉林百年汉克制药有限公司 | 一种利巴韦林注射液药物组合物及其制备方法和应用 |
CN110702677A (zh) * | 2019-12-16 | 2020-01-17 | 广州智汇生物科技有限公司 | 保健品中非法添加利巴韦林的检测方法 |
CN111812241A (zh) * | 2020-07-17 | 2020-10-23 | 广东华南药业集团有限公司 | 一种利巴韦林的分析方法及其应用 |
CN113030356A (zh) * | 2019-12-09 | 2021-06-25 | 武汉九州钰民医药科技有限公司 | 利巴韦林原料或制剂中有关物质的分离分析检测方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102366401A (zh) * | 2011-09-28 | 2012-03-07 | 河南辅仁怀庆堂制药有限公司 | 利巴韦林注射液及其生产工艺 |
EP2690092A1 (en) * | 2009-06-18 | 2014-01-29 | Concert Pharmaceuticals Inc. | Deuterated isoindoline-1,3-dione derivatives as PDE4 and TNF-alpha inhibitors |
-
2015
- 2015-10-13 CN CN201510656048.2A patent/CN105301127B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2690092A1 (en) * | 2009-06-18 | 2014-01-29 | Concert Pharmaceuticals Inc. | Deuterated isoindoline-1,3-dione derivatives as PDE4 and TNF-alpha inhibitors |
CN102366401A (zh) * | 2011-09-28 | 2012-03-07 | 河南辅仁怀庆堂制药有限公司 | 利巴韦林注射液及其生产工艺 |
Non-Patent Citations (4)
Title |
---|
吴宏富等: "反相高效液相色谱法测定利巴韦林注射液的含量和有关物质", 《安徽医药》 * |
吴宏富等: "反相高效液相色谱法测定利巴韦林注射液的有关物质", 《药物鉴定》 * |
张勤仓等: "利巴韦林片有关物质测定方法的建立", 《药物与临床》 * |
王丽等: "对《中国药典》2010 年版利巴韦林注射液有关物质检查方法的探讨", 《药学与临床研究》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108434095A (zh) * | 2018-06-19 | 2018-08-24 | 吉林百年汉克制药有限公司 | 一种利巴韦林注射液药物组合物及其制备方法和应用 |
CN113030356A (zh) * | 2019-12-09 | 2021-06-25 | 武汉九州钰民医药科技有限公司 | 利巴韦林原料或制剂中有关物质的分离分析检测方法 |
CN110702677A (zh) * | 2019-12-16 | 2020-01-17 | 广州智汇生物科技有限公司 | 保健品中非法添加利巴韦林的检测方法 |
CN110702677B (zh) * | 2019-12-16 | 2020-04-10 | 广州智汇生物科技有限公司 | 保健品中非法添加利巴韦林的检测方法 |
CN111812241A (zh) * | 2020-07-17 | 2020-10-23 | 广东华南药业集团有限公司 | 一种利巴韦林的分析方法及其应用 |
CN111812241B (zh) * | 2020-07-17 | 2023-02-14 | 广东华南药业集团有限公司 | 一种利巴韦林的分析方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN105301127B (zh) | 2018-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102980961B (zh) | 鳗鱼中孔雀石绿、结晶紫及其残留物检测的前处理方法 | |
CN101290306B (zh) | 一种乳及乳制品中四环素类抗生素残留量的检测方法 | |
CN105301127A (zh) | 一种利巴韦林药物组合物及其有关物质检测方法 | |
CN104777243B (zh) | 一种同时测定半夏中有机酸、核苷和麻黄碱的hplc方法 | |
CN103076409B (zh) | 奥拉西坦及其杂质的分析检测方法 | |
CN107315059B (zh) | 一种利福平胶囊中利福平及其杂质的含量测定方法 | |
CN101929985A (zh) | 一种用高效液相色谱法测定阿托伐他汀钙有关物质的方法 | |
CN103926332A (zh) | 一种同时测定半夏提取物中尿苷、鸟苷和腺苷含量的超高效液相色谱方法 | |
CN109580806A (zh) | 一种用于水产品中利福平药物残留的测定方法 | |
CN107957463A (zh) | 一种土壤中林可霉素残留量的检测方法 | |
CN103969374B (zh) | 一种桑叶中阿苯达唑持留量的测定方法 | |
CN104483404A (zh) | 一种开喉剑喷雾剂中岩白菜素的含量测定方法 | |
CN104374840A (zh) | 高效液相色谱法测定马来酸氯苯那敏乳膏中马来酸氯苯那敏含量的方法 | |
CN104523580A (zh) | 一种肌苷氯化钠注射液及其制备方法 | |
CN105675755A (zh) | 一种基于hplc的青钱柳中黄酮类化合物含量的检测方法 | |
CN105891389B (zh) | 一种提高肉中磺胺类药物残留测定准确度的前处理方法 | |
CN105974000B (zh) | 7-苯甲酰基-1,3-二氢吲哚-2-酮在奈帕芬胺稳定性质量控制中的用途 | |
CN104237399A (zh) | 测定安立生坦原料药及其制剂含量的方法 | |
CN102375044B (zh) | 一种盐酸苯达莫司汀中间体z6有关物质的分析方法 | |
CN114137120A (zh) | 一种雷帕霉素药物支架中有关物质的检测方法 | |
CN105388221A (zh) | 一种甲磺酸帕珠沙星质量检测方法 | |
CN104678006B (zh) | 一种苹果酸舒尼替尼有关物质分析方法 | |
CN106932347A (zh) | 一种美洛西林酸及其质量指标检测方法 | |
CN108508117A (zh) | 富马酸卢帕他定片有关物质控制方法 | |
CN104897589B (zh) | 一种定量评估药物溶血性指标的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a ribavirin pharmaceutical composition and a detection method of its related substances Effective date of registration: 20210730 Granted publication date: 20180918 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021430000029 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211014 Granted publication date: 20180918 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021430000029 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
CP02 | Change in the address of a patent holder |
Address after: No.8 Kangpu Avenue, high tech Industrial Park, Hanshou County, Changde City, Hunan Province, 415900 Patentee after: KAMP PHARMACEUTICALS Co.,Ltd. Address before: 12 / F, building B, Lugu information port, 658 Lugu Avenue, high tech Zone, Changsha City, Hunan Province, 410205 Patentee before: KAMP PHARMACEUTICALS Co.,Ltd. |
|
CP02 | Change in the address of a patent holder | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a ribavirin pharmaceutical composition and a detection method of its related substances Effective date of registration: 20211028 Granted publication date: 20180918 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021980011259 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |